Your browser doesn't support javascript.
loading
Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data.
Rothwell, Joseph A; Jenab, Mazda; Karimi, Mojgan; Truong, Thérèse; Mahamat-Saleh, Yahya; Ferrari, Pietro; Dashti, S Ghazaleh; Kühn, Tilman; Cross, Amanda J; Severi, Gianluca; Gunter, Marc J; Murphy, Neil.
Afiliação
  • Rothwell JA; Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Gustave Roussy, F-94805, Villejuif, France. Electronic address: joseph.rothwell@inserm.fr.
  • Jenab M; Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.
  • Karimi M; Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Gustave Roussy, F-94805, Villejuif, France.
  • Truong T; Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Gustave Roussy, F-94805, Villejuif, France.
  • Mahamat-Saleh Y; Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Gustave Roussy, F-94805, Villejuif, France.
  • Ferrari P; Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.
  • Dashti SG; Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Royal Children's Hospital, Victoria, Australia.
  • Kühn T; Institute for Global Food Security (IGFS), Queen's University Belfast, United Kingdom; Heidelberg Institute of Global Health (HIGH), University of Heidelberg, Heidelberg, Germany.
  • Cross AJ; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
  • Severi G; Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Gustave Roussy, F-94805, Villejuif, France; Department of Statistics, Computer Science, Applications "G. Parenti," University of Florence, Italy.
  • Gunter MJ; Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.
  • Murphy N; Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.
Clin Gastroenterol Hepatol ; 20(6): e1338-e1352, 2022 06.
Article em En | MEDLINE | ID: mdl-34687971
ABSTRACT
BACKGROUND &

AIMS:

Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown.

METHODS:

We investigated the associations between MetS and gastrointestinal cancer risk (overall, colorectal, pancreatic, esophageal adenocarcinoma, esophageal squamous cell carcinoma, stomach cardia, stomach non-cardia, hepatocellular carcinoma, and intrahepatic bile duct cancer) in 366,016 United Kingdom Biobank participants with comprehensive serum biomarker and genotype data. MetS status was determined by 3 different definitions at baseline, and, in 15,152 participants, at a repeat assessment after a median of 4.3 years of follow-up. Multivariable hazard ratios and 95% confidence intervals for cancer outcomes were estimated using Cox proportional hazards models. Analyses stratified by polygenic risk score were conducted for colorectal and pancreatic cancers.

RESULTS:

During a median follow-up of 7.1 years, 4238 incident cases of a gastrointestinal cancer occurred. MetS at baseline was associated with higher risk of overall gastrointestinal cancer by any definition (hazard ratio, 1.21; 95% confidence interval, 1.13-1.29, harmonized definition). MetS was associated with increased risks of colorectal cancer, colon cancer, rectal cancer, hepatocellular carcinoma, pancreatic cancer in women, and esophageal adenocarcinoma in men. Associations for colorectal cancer and pancreatic cancer did not differ by polygenic risk score strata (P-heterogeneity 0.70 and 0.69, respectively), and 80% of participants with MetS at baseline retained this status at the repeat assessment.

CONCLUSIONS:

These findings underscore the importance of maintaining good metabolic health in reducing the burden of gastrointestinal cancers, irrespective of genetic predisposition.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Neoplasias Retais / Neoplasias Esofágicas / Adenocarcinoma / Carcinoma Hepatocelular / Síndrome Metabólica / Carcinoma de Células Escamosas do Esôfago / Neoplasias Hepáticas Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Neoplasias Retais / Neoplasias Esofágicas / Adenocarcinoma / Carcinoma Hepatocelular / Síndrome Metabólica / Carcinoma de Células Escamosas do Esôfago / Neoplasias Hepáticas Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article